The civilization-versus-survival dial metaphor for mTOR activity assumes a systemic tradeoff: global anabolism versus global maintenance. Yet evidence suggests tissue-specific needs. Neurons require constant autophagy for proteostasis, while intestinal stem cells demand high mTOR for rapid renewal. Hypothesis: Longevity optimization depends not on systemic mTOR suppression, but on maintaining tissue-specific mTOR activity gradients that are disrupted during aging.

Proposed Mechanism

• Calibration via nutrient-sensing heterogeneity: Different tissues express varying levels of AMPK, sirtuins, and REDD1, creating intrinsic mTOR sensitivity gradients [pmc.ncbi.nlm.nih.gov/articles/PMC6611156]. For example, high SIRT1 in neurons may suppress mTORC1 locally even during fed states.
• Aging disrupts gradients: Systemic inflammation and mitochondrial dysfunction [pmc.ncbi.nlm.nih.gov/articles/PMC7253058] may blunt AMPK signaling in some tissues (e.g., muscle) while hyperactivating mTOR in others (e.g., adipose), leading to inappropriate anabolism in post-mitotic tissues and impaired regeneration in stem cell niches.
• Centenarian variants may preserve gradients: Rare mTOR pathway variants in centenarians [www.nad.com/news/the-secret-to-a-long-life-may-be-hidden-in-the-mtor-pathway-german-scientists-find] might not globally inhibit mTOR, but rather maintain youthful tissue-specific patterns.

Testable Predictions

1. Tissue-specific mTOR activity mapping in aging mice will show loss of gradient homogeneity (e.g., elevated mTOR in brain, suppressed in gut stem cells) compared to young controls.
2. Rapamycin's benefits will correlate with restoration of tissue-specific gradients, not uniform mTOR suppression. Low-dose, pulsed rapamycin may optimize gradients better than chronic dosing.
3. GH/IGF-1 modulation will have tissue-dependent effects: GH suppression in adipose/muscle may extend lifespan, but suppression in hematopoietic stem cells will cause immunosenescence, explaining why complete GH deficiency causes obesity and dysregulation despite longevity benefits.

Falsification Criteria

• If tissue-specific mTOR gradients do not exist or do not change with age, the hypothesis is false.
• If rapamycin uniformly suppresses mTOR across all tissues without gradient restoration, yet still extends lifespan, the gradient mechanism is unsupported.
• If GH replacement in elderly humans uniformly increases cancer risk regardless of tissue targeting, systemic mTOR activity is more dominant than tissue-specific effects.

Why This Matters

The civilization metaphor breaks down if cells in one tissue are "building civilization" while others are in "survival mode." Longevity may require not dialing down the whole system, but re-establishing the spatial organization of growth signals. Current interventions (rapamycin, GH suppression) may work partly by restoring gradients, but optimized therapies would target specific tissues—activating mTOR in stem cell niches while suppressing it in post-mitotic tissues. This reframes the tradeoff from a binary dial to a multi-dimensional calibration problem.